Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

1.

Nontuberculous Mycobacteria Show Differential Infectivity and Use Phospholipids to Antagonize LL-37.

Honda JR, Hess T, Carlson R, Kandasamy P, Nieto Ramirez LM, Norton GJ, Virdi R, Islam MN, Mehaffy C, Hasan NA, Epperson LE, Hesser D, Alper S, Strong M, Flores SC, Voelker DR, Dobos KM, Chan ED.

Am J Respir Cell Mol Biol. 2019 Sep 23. doi: 10.1165/rcmb.2018-0278OC. [Epub ahead of print]

PMID:
31545652
2.

Protein profile of different cellular fractions from Mycobacterium tuberculosis strains after exposure to isoniazid.

Nieto Ramirez LM, Mehaffy C, Dobos KM.

Data Brief. 2019 Apr 25;24:103953. doi: 10.1016/j.dib.2019.103953. eCollection 2019 Jun.

3.

Mycobacteria and their sweet proteins: An overview of protein glycosylation and lipoglycosylation in M. tuberculosis.

Mehaffy C, Belisle JT, Dobos KM.

Tuberculosis (Edinb). 2019 Mar;115:1-13. doi: 10.1016/j.tube.2019.01.001. Epub 2019 Jan 14. Review.

PMID:
30948163
4.

Deciphering the molecular basis of mycobacteria and lipoglycan recognition by the C-type lectin Dectin-2.

Decout A, Silva-Gomes S, Drocourt D, Blattes E, Rivière M, Prandi J, Larrouy-Maumus G, Caminade AM, Hamasur B, Källenius G, Kaur D, Dobos KM, Lucas M, Sutcliffe IC, Besra GS, Appelmelk BJ, Gilleron M, Jackson M, Vercellone A, Tiraby G, Nigou J.

Sci Rep. 2018 Nov 15;8(1):16840. doi: 10.1038/s41598-018-35393-5.

5.

Moving toward Tuberculosis Elimination. Critical Issues for Research in Diagnostics and Therapeutics for Tuberculosis Infection.

Keshavjee S, Amanullah F, Cattamanchi A, Chaisson R, Dobos KM, Fox GJ, Gendelman HE, Gordon R, Hesseling A, Le Van H, Kampmann B, Kana B, Khuller G, Lewinsohn DM, Lewinsohn DA, Lin PL, Lu LL, Maartens G, Owen A, Protopopova M, Rengarajan J, Rubin E, Salgame P, Schurr E, Seddon JA, Swindells S, Tobin DM, Udwadia Z, Walzl G, Srinivasan S, Rustomjee R, Nahid P.

Am J Respir Crit Care Med. 2019 Mar 1;199(5):564-571. doi: 10.1164/rccm.201806-1053PP. No abstract available.

6.

Structural determinants in a glucose-containing lipopolysaccharide from Mycobacterium tuberculosis critical for inducing a subset of protective T cells.

De P, McNeil M, Xia M, Boot CM, Hesser DC, Denef K, Rithner C, Sours T, Dobos KM, Hoft D, Chatterjee D.

J Biol Chem. 2018 Jun 22;293(25):9706-9717. doi: 10.1074/jbc.RA118.002582. Epub 2018 May 1.

7.

Protein Digestion, Ultrafiltration, and Size Exclusion Chromatography to Optimize the Isolation of Exosomes from Human Blood Plasma and Serum.

Diaz G, Bridges C, Lucas M, Cheng Y, Schorey JS, Dobos KM, Kruh-Garcia NA.

J Vis Exp. 2018 Apr 13;(134). doi: 10.3791/57467.

8.

Cytokine-Mediated Systemic Adverse Drug Reactions in a Drug-Drug Interaction Study of Dolutegravir With Once-Weekly Isoniazid and Rifapentine.

Brooks KM, George JM, Pau AK, Rupert A, Mehaffy C, De P, Dobos KM, Kellogg A, McLaughlin M, McManus M, Alfaro RM, Hadigan C, Kovacs JA, Kumar P.

Clin Infect Dis. 2018 Jul 2;67(2):193-201. doi: 10.1093/cid/ciy082.

9.

The N-terminal peptide moiety of the Mycobacterium tuberculosis 19 kDa lipoprotein harbors RP105-agonistic properties.

Schultz TE, Wiesmüller KH, Lucas M, Dobos KM, Baxter AG, Blumenthal A.

J Leukoc Biol. 2018 Feb;103(2):311-319. doi: 10.1002/JLB.2MA0517-190RR. Epub 2018 Jan 9.

PMID:
29345364
10.

HLA-E Presents Glycopeptides from the Mycobacterium tuberculosis Protein MPT32 to Human CD8+ T cells.

Harriff MJ, Wolfe LM, Swarbrick G, Null M, Cansler ME, Canfield ET, Vogt T, Toren KG, Li W, Jackson M, Lewinsohn DA, Dobos KM, Lewinsohn DM.

Sci Rep. 2017 Jul 4;7(1):4622. doi: 10.1038/s41598-017-04894-0.

11.

Second generation multiple reaction monitoring assays for enhanced detection of ultra-low abundance Mycobacterium tuberculosis peptides in human serum.

Mehaffy C, Dobos KM, Nahid P, Kruh-Garcia NA.

Clin Proteomics. 2017 Jun 5;14:21. doi: 10.1186/s12014-017-9156-y. eCollection 2017.

12.

Changes in the Membrane-Associated Proteins of Exosomes Released from Human Macrophages after Mycobacterium tuberculosis Infection.

Diaz G, Wolfe LM, Kruh-Garcia NA, Dobos KM.

Sci Rep. 2016 Nov 29;6:37975. doi: 10.1038/srep37975.

13.

Virulence of Mycobacterium tuberculosis after Acquisition of Isoniazid Resistance: Individual Nature of katG Mutants and the Possible Role of AhpC.

Nieto R LM, Mehaffy C, Creissen E, Troudt J, Troy A, Bielefeldt-Ohmann H, Burgos M, Izzo A, Dobos KM.

PLoS One. 2016 Nov 28;11(11):e0166807. doi: 10.1371/journal.pone.0166807. eCollection 2016.

14.

A Subset of Protective γ9δ2 T Cells Is Activated by Novel Mycobacterial Glycolipid Components.

Xia M, Hesser DC, De P, Sakala IG, Spencer CT, Kirkwood JS, Abate G, Chatterjee D, Dobos KM, Hoft DF.

Infect Immun. 2016 Aug 19;84(9):2449-62. doi: 10.1128/IAI.01322-15. Print 2016 Sep.

15.

Boosting BCG-primed responses with a subunit Apa vaccine during the waning phase improves immunity and imparts protection against Mycobacterium tuberculosis.

Nandakumar S, Kannanganat S, Dobos KM, Lucas M, Spencer JS, Amara RR, Plikaytis BB, Posey JE, Sable SB.

Sci Rep. 2016 May 13;6:25837. doi: 10.1038/srep25837.

16.

Longitudinal whole genome analysis of pre and post drug treatment Mycobacterium tuberculosis isolates reveals progressive steps to drug resistance.

Datta G, Nieto LM, Davidson RM, Mehaffy C, Pederson C, Dobos KM, Strong M.

Tuberculosis (Edinb). 2016 May;98:50-5. doi: 10.1016/j.tube.2016.02.004. Epub 2016 Feb 26.

17.

Comparing isogenic strains of Beijing genotype Mycobacterium tuberculosis after acquisition of Isoniazid resistance: A proteomics approach.

Nieto R LM, Mehaffy C, Dobos KM.

Proteomics. 2016 May;16(9):1376-80. doi: 10.1002/pmic.201500403. Epub 2016 Apr 13.

18.

RP105 Engages Phosphatidylinositol 3-Kinase p110δ To Facilitate the Trafficking and Secretion of Cytokines in Macrophages during Mycobacterial Infection.

Yu CH, Micaroni M, Puyskens A, Schultz TE, Yeo JC, Stanley AC, Lucas M, Kurihara J, Dobos KM, Stow JL, Blumenthal A.

J Immunol. 2015 Oct 15;195(8):3890-900. doi: 10.4049/jimmunol.1500017. Epub 2015 Sep 14.

19.

Pathogenic nontuberculous mycobacteria resist and inactivate cathelicidin: implication of a novel role for polar mycobacterial lipids.

Honda JR, Hess T, Malcolm KC, Ovrutsky AR, Bai X, Irani VR, Dobos KM, Chan ED, Flores SC.

PLoS One. 2015 May 18;10(5):e0126994. doi: 10.1371/journal.pone.0126994. eCollection 2015.

20.

Analysis of the metabolome of Anopheles gambiae mosquito after exposure to Mycobacterium ulcerans.

Hoxmeier JC, Thompson BD, Broeckling CD, Small P, Foy BD, Prenni J, Dobos KM.

Sci Rep. 2015 Mar 18;5:9242. doi: 10.1038/srep09242.

21.

Fractionation and analysis of mycobacterial proteins.

Lucas MC, Wolfe LM, Hazenfield RM, Kurihara J, Kruh-Garcia NA, Belisle J, Dobos KM.

Methods Mol Biol. 2015;1285:47-75. doi: 10.1007/978-1-4939-2450-9_4.

PMID:
25779310
22.

Deciphering the role of exosomes in tuberculosis.

Kruh-Garcia NA, Wolfe LM, Dobos KM.

Tuberculosis (Edinb). 2015 Jan;95(1):26-30. doi: 10.1016/j.tube.2014.10.010. Epub 2014 Nov 21. Review.

PMID:
25496995
23.

Detection of Mycobacterium tuberculosis peptides in the exosomes of patients with active and latent M. tuberculosis infection using MRM-MS.

Kruh-Garcia NA, Wolfe LM, Chaisson LH, Worodria WO, Nahid P, Schorey JS, Davis JL, Dobos KM.

PLoS One. 2014 Jul 31;9(7):e103811. doi: 10.1371/journal.pone.0103811. eCollection 2014.

24.

The human antibody response to the surface of Mycobacterium tuberculosis.

Perley CC, Frahm M, Click EM, Dobos KM, Ferrari G, Stout JE, Frothingham R.

PLoS One. 2014 Jun 11;9(2):e98938. doi: 10.1371/journal.pone.0098938. eCollection 2014.

25.

HspX vaccination and role in virulence in the guinea pig model of tuberculosis.

Wieczorek AE, Troudt JL, Knabenbauer P, Taylor J, Pavlicek RL, Karls R, Hess A, Davidson RM, Strong M, Bielefeldt-Ohmann H, Izzo AA, Dobos KM.

Pathog Dis. 2014 Aug;71(3):315-25. doi: 10.1111/2049-632X.12147. Epub 2014 Feb 24.

26.

O-mannosylation of the Mycobacterium tuberculosis adhesin Apa is crucial for T cell antigenicity during infection but is expendable for protection.

Nandakumar S, Kannanganat S, Dobos KM, Lucas M, Spencer JS, Fang S, McDonald MA, Pohl J, Birkness K, Chamcha V, Ramirez MV, Plikaytis BB, Posey JE, Amara RR, Sable SB.

PLoS Pathog. 2013;9(10):e1003705. doi: 10.1371/journal.ppat.1003705. Epub 2013 Oct 10.

27.

Antigen 85 variation across lineages of Mycobacterium tuberculosis-implications for vaccine and biomarker success.

Kruh-Garcia NA, Murray M, Prucha JG, Dobos KM.

J Proteomics. 2014 Jan 31;97:141-50. doi: 10.1016/j.jprot.2013.07.005. Epub 2013 Jul 24.

28.

A chemical proteomics approach to profiling the ATP-binding proteome of Mycobacterium tuberculosis.

Wolfe LM, Veeraraghavan U, Idicula-Thomas S, Schürer S, Wennerberg K, Reynolds R, Besra GS, Dobos KM.

Mol Cell Proteomics. 2013 Jun;12(6):1644-60. doi: 10.1074/mcp.M112.025635. Epub 2013 Mar 5.

29.

Autophagy protects against active tuberculosis by suppressing bacterial burden and inflammation.

Castillo EF, Dekonenko A, Arko-Mensah J, Mandell MA, Dupont N, Jiang S, Delgado-Vargas M, Timmins GS, Bhattacharya D, Yang H, Hutt J, Lyons CR, Dobos KM, Deretic V.

Proc Natl Acad Sci U S A. 2012 Nov 13;109(46):E3168-76. doi: 10.1073/pnas.1210500109. Epub 2012 Oct 23.

30.

HspX-mediated protection against tuberculosis depends on its chaperoning of a mycobacterial molecule.

Taylor JL, Wieczorek A, Keyser AR, Grover A, Flinkstrom R, Karls RK, Bielefeldt-Ohmann H, Dobos KM, Izzo AA.

Immunol Cell Biol. 2012 Nov;90(10):945-54. doi: 10.1038/icb.2012.34. Epub 2012 Jul 17.

31.

Purified protein derivatives of tuberculin--past, present, and future.

Yang H, Kruh-Garcia NA, Dobos KM.

FEMS Immunol Med Microbiol. 2012 Dec;66(3):273-80. doi: 10.1111/j.1574-695X.2012.01002.x. Epub 2012 Aug 1. Review.

32.

Deciphering the proteome of the in vivo diagnostic reagent "purified protein derivative" from Mycobacterium tuberculosis.

Cho YS, Dobos KM, Prenni J, Yang H, Hess A, Rosenkrands I, Andersen P, Ryoo SW, Bai GH, Brennan MJ, Izzo A, Bielefeldt-Ohmann H, Belisle JT.

Proteomics. 2012 Apr;12(7):979-91. doi: 10.1002/pmic.201100544.

33.

Prospective on Mycobacterium tuberculosis proteomics.

Mehaffy MC, Kruh-Garcia NA, Dobos KM.

J Proteome Res. 2012 Jan 1;11(1):17-25. doi: 10.1021/pr2008658. Epub 2011 Oct 19. Review.

PMID:
21988637
34.

Three protein cocktails mediate delayed-type hypersensitivity responses indistinguishable from that elicited by purified protein derivative in the guinea pig model of Mycobacterium tuberculosis infection.

Yang H, Troudt J, Grover A, Arnett K, Lucas M, Cho YS, Bielefeldt-Ohmann H, Taylor J, Izzo A, Dobos KM.

Infect Immun. 2011 Feb;79(2):716-23. doi: 10.1128/IAI.00486-10. Epub 2010 Dec 6.

35.

The non-clonality of drug resistance in Beijing-genotype isolates of Mycobacterium tuberculosis from the Western Cape of South Africa.

Ioerger TR, Feng Y, Chen X, Dobos KM, Victor TC, Streicher EM, Warren RM, Gey van Pittius NC, Van Helden PD, Sacchettini JC.

BMC Genomics. 2010 Nov 26;11:670. doi: 10.1186/1471-2164-11-670.

36.

Portrait of a pathogen: the Mycobacterium tuberculosis proteome in vivo.

Kruh NA, Troudt J, Izzo A, Prenni J, Dobos KM.

PLoS One. 2010 Nov 11;5(11):e13938. doi: 10.1371/journal.pone.0013938.

37.

Proteomic definition of the cell wall of Mycobacterium tuberculosis.

Wolfe LM, Mahaffey SB, Kruh NA, Dobos KM.

J Proteome Res. 2010 Nov 5;9(11):5816-26. doi: 10.1021/pr1005873. Epub 2010 Sep 29.

38.

Proteomic analysis identifies highly antigenic proteins in exosomes from M. tuberculosis-infected and culture filtrate protein-treated macrophages.

Giri PK, Kruh NA, Dobos KM, Schorey JS.

Proteomics. 2010 Sep;10(17):3190-202. doi: 10.1002/pmic.200900840.

39.

Variation among genome sequences of H37Rv strains of Mycobacterium tuberculosis from multiple laboratories.

Ioerger TR, Feng Y, Ganesula K, Chen X, Dobos KM, Fortune S, Jacobs WR Jr, Mizrahi V, Parish T, Rubin E, Sassetti C, Sacchettini JC.

J Bacteriol. 2010 Jul;192(14):3645-53. doi: 10.1128/JB.00166-10. Epub 2010 May 14.

40.

Descriptive proteomic analysis shows protein variability between closely related clinical isolates of Mycobacterium tuberculosis.

Mehaffy C, Hess A, Prenni JE, Mathema B, Kreiswirth B, Dobos KM.

Proteomics. 2010 May;10(10):1966-84. doi: 10.1002/pmic.200900836.

41.

A murine DC-SIGN homologue contributes to early host defense against Mycobacterium tuberculosis.

Tanne A, Ma B, Boudou F, Tailleux L, Botella H, Badell E, Levillain F, Taylor ME, Drickamer K, Nigou J, Dobos KM, Puzo G, Vestweber D, Wild MK, Marcinko M, Sobieszczuk P, Stewart L, Lebus D, Gicquel B, Neyrolles O.

J Exp Med. 2009 Sep 28;206(10):2205-20. doi: 10.1084/jem.20090188. Epub 2009 Sep 21.

42.

Deciphering the proteomic profile of Mycobacterium leprae cell envelope.

Marques MA, Neves-Ferreira AG, da Silveira EK, Valente RH, Chapeaurouge A, Perales J, da Silva Bernardes R, Dobos KM, Spencer JS, Brennan PJ, Pessolani MC.

Proteomics. 2008 Jun;8(12):2477-91. doi: 10.1002/pmic.200700971.

PMID:
18563741
43.

Conserved mycobacterial lipoglycoproteins activate TLR2 but also require glycosylation for MHC class II-restricted T cell activation.

Sieling PA, Hill PJ, Dobos KM, Brookman K, Kuhlman AM, Fabri M, Krutzik SR, Rea TH, Heaslip DG, Belisle JT, Modlin RL.

J Immunol. 2008 May 1;180(9):5833-42.

44.

Demonstration of components of antigen 85 complex in cerebrospinal fluid of tuberculous meningitis patients.

Kashyap RS, Dobos KM, Belisle JT, Purohit HJ, Chandak NH, Taori GM, Daginawala HF.

Clin Diagn Lab Immunol. 2005 Jun;12(6):752-8.

45.

Mycobacterium tuberculosis functional network analysis by global subcellular protein profiling.

Mawuenyega KG, Forst CV, Dobos KM, Belisle JT, Chen J, Bradbury EM, Bradbury AR, Chen X.

Mol Biol Cell. 2005 Jan;16(1):396-404. Epub 2004 Nov 3.

46.

Buruli ulcer and schistosomiasis: no association found.

Stienstra Y, van der Werf TS, van der Graaf WT, Secor WE, Kihlstrom SL, Dobos KM, Asamoa K, Quarshi E, Etuaful SN, Klutse EY, King CH.

Am J Trop Med Hyg. 2004 Sep;71(3):318-21.

PMID:
15381813
47.

Continued proteomic analysis of Mycobacterium leprae subcellular fractions.

Marques MA, Espinosa BJ, Xavier da Silveira EK, Pessolani MC, Chapeaurouge A, Perales J, Dobos KM, Belisle JT, Spencer JS, Brennan PJ.

Proteomics. 2004 Oct;4(10):2942-53.

PMID:
15378742
48.

Mycobacterium tuberculosis LprG (Rv1411c): a novel TLR-2 ligand that inhibits human macrophage class II MHC antigen processing.

Gehring AJ, Dobos KM, Belisle JT, Harding CV, Boom WH.

J Immunol. 2004 Aug 15;173(4):2660-8.

49.

A limited antigen-specific cellular response is sufficient for the early control of Mycobacterium tuberculosis in the lung but is insufficient for long-term survival.

Turner J, Dobos KM, Keen MA, Frank AA, Ehlers S, Orme IM, Belisle JT, Cooper AM.

Infect Immun. 2004 Jul;72(7):3759-68.

50.

Proteomic approaches to antigen discovery.

Dobos KM, Spencer JS, Orme IM, Belisle JT.

Methods Mol Med. 2004;94:3-17.

PMID:
14959819

Supplemental Content

Loading ...
Support Center